Current Clinical Trials

ADULT CANCER RESEARCH

• Breast
• Alliance A191901: Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions
• Alliance A212102: Blinded Reference Set for Multicancer Early Detection Blood Tests
• SWOG S2010: A Randomized Phase III Trial Comparing Active Symptom Monitoring Plus Patient Education Versus Patient Education Alone to Improve Persistence with Endocrine Therapy in Young Women with Stage I-III Breast Cancer (ASPEN)
• NRG-CC011: Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors: A Multi-Center Randomized Double-Blinded Controlled Trial
• ML43171: A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With Exemestane Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
• SWOG S2212: Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study
• Latimer breast cancer fresh tissue and blood study (Biomarker)
• Retrospective analyses of genetic testing performed in patients with breast, ovarian and endometrial cancer
• Endometrial
• GOG-3083: A Phase 3, Randomized, Placebo-controlled, Double-blind, Multicenter Trial Of Selinexor In Maintenance Therapy after systemic Therapy For Patients With P53 Wild-type, Advanced Or Recurrent Endometrial Carcinoma
• NRG-GY-026: Testing the Addition of Trastuzumab or Trastuzumab/Pertuzumab to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma Open to accrual: Upfront treatment for stage I-IV uterine serous carcinoma or carcinosarcoma
• GOG-3038: An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204)
• Ovarian
• GOG-3078: Platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancers using an antibody drug conjugate
• GOG-3086: A Phase 2 Open-label Study Evaluating the Efficacy and Safety of Luveltamab Tazevibulin (STRO-002) in Women with Relapsed Platinum-resistant Epithelial Ovarian Cancer (including Fallopian Tube or Primary Peritoneal Cancers) Expressing Folate Receptor alpha (FOLR1) (Ovarian); Awaiting IRB Approval; Awaiting Contract
• Head and Neck
• The efficacy of topical fibrin sealant in the reduction of postoperative pain after head and neck surgery
• Biospecimen
• Utility of molecular diagnostics from cervicovaginal sampling in endometrial cancer
• SERATRIALS-18004: A Multi-Center Study for the Collection of Biospecimens for Research; Surplus Surgical Tissues and Surplus/Non-Surplus Biofluids for In-Vitro Research
• MTG-022: Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized Management of Patients
• Other
• A012103: OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
• AZUR2: A Phase 3, Open-Label, Randomized Study of Perioperative Dostarlimab Monotherapy versus Standard of Care in Participants with Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
• GOG-3105: A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
• Moonshot: National Cancer Institute / Cancer Moonshot Biobank Research Protocol
• NRG-GY026: A Phase II/III study of paclitaxel/carboplatin alone or combined with either trastuzumab and hyaluronidase-oysk (HERCEPTIN HYLECTA) or pertuzumab trastuzumab and hyaluronidase-zzfx (PHESGO) in HER2 positive, stage I-IV endometrial serous carcinoma or carcinosarcoma

CARDIOVASCULAR RESEARCH

• AIM HIGHer: Assessment of Implantable CCM in the Heart Failure Group with Higher Ejection Fraction (AIM HIGHer)
• INTEGRA-D: Assessment of the Safety and Efficacy of a Combined Cardiac Contractility Modulation and Implantable Cardioverter Defibrillator Device for Subjects with Heart Failure and Reduced Ejection Fracture
• HATS OFF: An NIH-funded FDA clinical trial to evaluate HEMOTAG, a non-invasive cardiac assessment and clinical decision support tool
• Librexa Afib Study: A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation

PEDIATRIC CANCER

• Leukemia
• AALL1631: A Children’s Oncology Protocol for an International Phase III Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Ph+ ALL Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbone
• AALL1731: A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)
• AALL1732: A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND# 133494, NSC# 772518) for Newly Diagnosed High-risk B-ALL; Risk-Adapted Post-induction Therapy for High-risk B-ALL, Mixed Phenotype Acute Leukemia and Disseminated B-LLy

• Renal/Kidney
• AREN03B2: A Children’s Oncology Group Protocol for Study of Kidney Tumors in Younger Patient

• Other
• ALTE05N1: A Children’s Oncology Protocol for Long-Term Follow-Up of Patients Who Have Participated in COG Studies
• APEC1621: A Children's Oncology Protocol for MATCH (Molecular Analysis for Therapy Choice) Examining Molecular Changes Using Genomic Sequencing Technologies in Refractory/Recurrent Tumors in Children and Adolescents
• AGCT1532: A Randomized Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-risk Metastatic Germ Cell Tumors
• APEC14B1: A Children’s Oncology Protocol for Project: Every Child: A Registry, Eligibility Screening, Biology, and Outcome Study
• ACCL20N1CD: Financial Distress During Treatment for Pediatric Acute Lymphoblastic Leukemia in the United States
• ALTE1631: A Randomized Web-Based Physical Activity Intervention Among Children and Adolescents With Cancer
• AGCT1531: A Phase 3 Study of Active Surveillance for Low Risk and A Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
• ARST2031: A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, nad Cyclophosphamide (VINO-AC) vs. Vincristine, Dactinomycin and Cyclophosphamide (VAC) Plus VINO-CPO Maintenance in Patients with High Risk Rhabdomyosarcoma (HR-RMS)
• AHOD2131: A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
• ANHL1931: A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
• APAL2020SC: Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias
• ARST2032: A Prospective Phase 3 Study of Patients With Newly Diagnosed Very Low-Risk and Low-Risk Fusion Negative Rhabdomyosarcoma
• DCP-001: Use of a Clinical Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)